| Lessons in comparative oncology |
| PH Sugarbaker |
|
JCO Jul 1 1991: 1099–1101.
[PDF]
|
 |
| Tumor markers of prognosis |
| RC Leonard |
|
JCO Jul 1 1991: 1102–1104.
[PDF]
|
|
|
A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584 |
| |
G Steele, Jr, R Bleday, RJ Mayer, A Lindblad, N Petrelli, and D Weaver |
| |
JCO Jul 1 1991: 1105–1112.
[Abstract]
[PDF]
|
|
|
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study |
| |
DF Hayes, R Mesa-Tejada, LD Papsidero, GA Croghan, AH Korzun, L Norton, W Wood, JA Strauchen, M Grimes, and RB Weiss |
| |
JCO Jul 1 1991: 1113–1123.
[Abstract]
[PDF]
|
|
|
Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes |
| |
A Moliterni, G Bonadonna, P Valagussa, L Ferrari, and M Zambetti |
| |
JCO Jul 1 1991: 1124–1130.
[Abstract]
[PDF]
|
|
|
A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer |
| |
C Trask, A Silverstone, CM Ash, H Earl, C Irwin, A Bakker, JS Tobias, and RL Souhami |
| |
JCO Jul 1 1991: 1131–1137.
[Abstract]
[PDF]
|
|
|
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience |
| |
GA Omura, MF Brady, HD Homesley, E Yordan, FJ Major, HJ Buchsbaum, and RC Park |
| |
JCO Jul 1 1991: 1138–1150.
[Abstract]
[PDF]
|
|
|
Corynebacterium parvum versus bacille Calmette-Guerin adjuvant immunotherapy of stage II malignant melanoma |
| |
A Lipton, HA Harvey, CM Balch, CE Antle, R Heckard, and AA Bartolucci |
| |
JCO Jul 1 1991: 1151–1156.
[Abstract]
[PDF]
|
|
|
A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study |
| |
JK Weick, J Crowley, RB Natale, BL Hom, S Rivkin, CA Coltman, Jr, SA Taylor, and RB Livingston |
| |
JCO Jul 1 1991: 1157–1162.
[Abstract]
[PDF]
|
|
|
Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol |
| |
CR Nichols, SD Williams, PJ Loehrer, FA Greco, ED Crawford, J Weetlaufer, ME Miller, A Bartolucci, L Schacter, and LH Einhorn |
| |
JCO Jul 1 1991: 1163–1172.
[Abstract]
[PDF]
|
|
|
Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study |
| |
RG Evans, ME Nesbit, EA Gehan, LA Garnsey, O Burgert, Jr, TJ Vietti, A Cangir, M Tefft, P Thomas, and FB Askin |
| |
JCO Jul 1 1991: 1173–1180.
[Abstract]
[PDF]
|
|
|
Postoperative treatment of nonmetastatic visible residual neuroblastoma: a Pediatric Oncology Group study |
| |
R Nitschke, EI Smith, G Altshuler, D Altmiller, J Shuster, A Green, R Castleberry, FA Hayes, B Golembe, and R Ducos |
| |
JCO Jul 1 1991: 1181–1188.
[Abstract]
[PDF]
|
|
|
Nonlymphoblastic lymphoma in children--histology and stage-related response to therapy: a Pediatric Oncology Group study |
| |
EV Hvizdala, C Berard, T Callihan, J Falletta, H Sabio, JJ Shuster, M Sullivan, and MD Wharam |
| |
JCO Jul 1 1991: 1189–1195.
[Abstract]
[PDF]
|
|
|
Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission |
| |
JC Weeks, BY Yeap, GP Canellos, and MA Shipp |
| |
JCO Jul 1 1991: 1196–1203.
[Abstract]
[PDF]
|
|
|
Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study |
| |
TP Miller, S Dahlberg, SE Salmon, SK Williamson, RJ Belt, BW Dana, and RI Fisher |
| |
JCO Jul 1 1991: 1204–1209.
[Abstract]
[PDF]
|
|
|
Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia |
| |
S Amadori, W Arcese, G Isacchi, G Meloni, MC Petti, B Monarca, AM Testi, and F Mandelli |
| |
JCO Jul 1 1991: 1210–1214.
[Abstract]
[PDF]
|
|
|
Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens |
| |
AC Braverman, JH Antin, MT Plappert, EF Cook, and RT Lee |
| |
JCO Jul 1 1991: 1215–1223.
[Abstract]
[PDF]
|
|
|
Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation |
| |
TJ Nevill, MJ Barnett, HG Klingemann, DE Reece, JD Shepherd, and GL Phillips |
| |
JCO Jul 1 1991: 1224–1232.
[Abstract]
[PDF]
|
|
|
Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial |
| |
RO Dillman, RK Oldham, KW Tauer, DW Orr, NM Barth, G Blumenschein, J Arnold, R Birch, and WH West |
| |
JCO Jul 1 1991: 1233–1240.
[Abstract]
[PDF]
|
|
|
Phase I study of recombinant human interleukin-3 in patients with bone marrow failure |
| |
R Kurzrock, M Talpaz, Z Estrov, MG Rosenblum, and JU Gutterman |
| |
JCO Jul 1 1991: 1241–1250.
[Abstract]
[PDF]
|
|
|
Phase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis |
| |
A Faradji, A Bohbot, H Frost, M Schmitt-Goguel, JC Siffert, P Dufour, M Eber, C Lallot, ML Wiesel, and JP Bergerat |
| |
JCO Jul 1 1991: 1251–1260.
[Abstract]
[PDF]
|
|
|
A phase I trial of taxol given by a 6-hour intravenous infusion |
| |
T Brown, K Havlin, G Weiss, J Cagnola, J Koeller, J Kuhn, J Rizzo, J Craig, J Phillips, and D Von Hoff |
| |
JCO Jul 1 1991: 1261–1267.
[Abstract]
[PDF]
|
|
|
Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy |
| |
G Fraschini, A Ciociola, L Esparza, D Templeton, FA Holmes, RS Walters, and GN Hortobagyi |
| |
JCO Jul 1 1991: 1268–1274.
[Abstract]
[PDF]
|
|
|
Cancer risk notification: psychosocial and ethical implications |
| |
C Lerman, BK Rimer, and PF Engstrom |
| |
JCO Jul 1 1991: 1275–1282.
[Abstract]
[PDF]
|
|
|
Tamoxifen in premenopausal patients with metastatic breast cancer: a review |
| |
MC Sunderland and CK Osborne |
| |
JCO Jul 1 1991: 1283–1297.
[Abstract]
[PDF]
|
|
|
Mycosis fungoides and the Sezary syndrome: a review of pathogenesis, diagnosis, and therapy |
| |
TM Kuzel, HH Roenigk, Jr, and ST Rosen |
| |
JCO Jul 1 1991: 1298–1313.
[Abstract]
[PDF]
|
|
|
Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes |
| |
RE Doblin and MA Kleiman |
| |
JCO Jul 1 1991: 1314–1319.
[Abstract]
[PDF]
|
|
| Who should pay? |
| JE White |
|
JCO Jul 1 1991: 1320a.
[PDF]
|
|
| Prognostic factors in aggressive lymphoma |
| WS Velasquez |
|
JCO Jul 1 1991: 1320b–1321.
[PDF]
|
|
| What were the received dose intensities in the three arms? |
| WM Hryniuk |
|
JCO Jul 1 1991: 1321–1322.
[PDF]
|
|
| What is the value of methotrexate in the treatment of advanced colorectal cancer? |
| MJ O'Connell, CG Moertel, and MA Poon |
|
JCO Jul 1 1991: 1322–1324.
[PDF]
|
|
